2021

1. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug

   Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1